IN8bio Inc. (INAB): Earnings growth forecast for next year

Symbol and logo of brand IN8bio, Inc. (INAB)

Investments in IN8bio, Inc. (INAB) are independent of market cycles, as demand for leukemia treatment remains stable. Consensus expectations for n+1 profit dynamics serve as a confidence indicator, where the 15.00 metric expresses the state of the indicator. Robotic bioreactors eliminate human error in T-cell production, while air delivery of materials from various laboratories ensures the continuity of all clinical trials.

INAB: IN8bio, Inc Consensus forecast of earnings per share growth for next year 07/04/2022 - 11/15/2026

Analytical breakdowns and data insights for company IN8bio Inc. (INAB)

- price and consensus price forecast:
Price Chart IN8bio Inc.|INAB - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization IN8bio Inc|INAB - Business Value
- book capitalization indicators:
Book Value per Share IN8bio|INAB - Book Valuation of Business|Market Value to Book Value Ratio in8bio.com|INAB - Total Business Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio IN8bio, Inc.|INAB - Long-Term Debt to Capital|Short-Term Debt to Equity IN8bio Inc.|INAB - Company Aggregate Debts|Debts to Net Assets IN8bio Inc.|INAB - Company Long-Term Debt|Short-Term Debt IN8bio|Intermediate Coverage Ratio in8bio.com
- earnings and valuation multiples information:
INAB - Net Profit|Company Profit Forecast IN8bio, Inc.|INAB - Price to Earnings Ratio|Price to Future Earnings Ratio in8bio.com|INAB - PEG Multiple|Enterprise Value to EBITDA Ratio IN8bio, Inc|INAB - Operating profit before deduction of amortization|Net earnings per share for the last four quarters IN8bio|INAB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months in8bio.com|INAB - Earnings per share growth in current year|Projected earnings per share growth rate for next year IN8bio, Inc.
- revenue and sales details:
INAB - Revenue and Sales Volume|Projected Sales Volume IN8bio Inc|INAB - P/S Multiple|Price-to-Projected Revenue Ratio IN8bio, Inc.
Basic company analysis:IN8bio, Inc. - INAB
Mass-produced product of IN8bio

This indicator determines investment reliability through a consolidated earnings per share (EPS) forecast, where any deviation from target growth rates signals a risk of asset impairment. By analyzing the forward-looking EPS growth vector for the coming year, investors assess the probability of commercializing IN8bio, Inc. (INAB) technology, specifically DeltaInk, whose patent protection and support within the US oncology sector mitigate stringent FDA oversight.

Key competitors

Net earnings per share growth forecast for next year TG Therapeutics Inc|Expected net earnings per share growth next year Arcellx ACLX|Earnings growth forecast for next year IRON|Syndax Pharmaceuticals Inc - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Kura Oncology Inc KURA|Earnings growth forecast for next year ADC Therapeutics Corp ADCT|FHTX - Net earnings per share growth forecast for next year|Expected earnings per share trend next year VOR (Vor Biopharma)|NKTX: Earnings growth forecast for next year|Expected net earnings per share growth next year Coeptis (COEP)|ATNM (Actinium Corp) - Earnings growth forecast for next year|ESLA: Expected earnings per share trend next year|Expected earnings per share growth for next year CASI (CASI Pharmaceuticals Inc.)|MRKR - Expected net earnings per share growth next year|Earnings growth forecast for next year ERNA (Eterna Therapeutics, Inc.)|GT Biopharma Inc (GTBP) - Expected net earnings per share growth next year|APTO: Expected earnings per share growth for next year|Bio-Path - Projected earnings per share increase next year|MEI Pharma, Inc. (MEIP) - Net earnings per share growth forecast for next year|Vincerx - Expected earnings per share trend next year